Methylphenidate derivatives and uses of them

Inactive Publication Date: 2006-08-24
AMPIO PHARMA
View PDF12 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] In a first embodiment, the invention provides a method of inhibiting angiogenesis in an animal. The method comprises administering an effective amount of a compound of formula I, or a pharmaceutically-acceptable salt or a prodrug thereof, to the animal.
[0008] In a second embodiment, the invention provides a method of treating an angiogenic disease or condition in an animal. The method comprises administering a

Problems solved by technology

However, there is some evidence that m

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methylphenidate derivatives and uses of them
  • Methylphenidate derivatives and uses of them
  • Methylphenidate derivatives and uses of them

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0105] Whole blood was drawn from GR283, a human volunteer with known allergies, into a glass vacutainer tube containing no anticoagulant. This blood was allowed to clot, and the serum was removed by centrifugation and then heat inactivated by placing it in a water bath at 56° C. for 30 minutes. Whole blood from GR283 was also drawn into a glass vacutainer tube containing heparin and used for peripheral blood lymphocytes (PBL) isolation as follows. Whole blood was layered over room temperature Histopaque 1077 solution and centrifuged at 2000 rpm for 15 minutes at room temperature. Cells at the plasma-Histopaque interface were then removed and washed with culture medium (IMDM medium with 10% heat-inactivated GR283 serum plus 1% penicillin / streptomycin) at 37° C.

[0106] The compound of formula II (see above) and methylphenidate (both obtained from Dr. Jeffrey D. Winkler, University of Pennsylvania, Philadelphia, Pa.) in culture medium were added to wells of a 96-well plate to give fin...

example 2

[0109] Whole blood was drawn from GR467, a human volunteer with known allergies, and processed as described in Example 1 to give heat-inactivated serum and PBL. The compound of formula II and methylphenidate in culture medium (made using heat-inactivated GR467 serum) were added to wells of a 96-well plate to give final concentrations of 5 μg / ml, 15 μg / ml and 25 μg / ml of the compound of formula II and 15 μg / ml methylphendiate. Water and dexamethasone (final concentration of 10 μM) were used as controls. Then, GR467's PBL in culture medium were added to the wells to give a final concentration of 150,000 cells per well, and the plates were incubated at 37° C., 5% CO2 for 24 hours. After this incubation, PHA was added to give a final concentration of 2 μg / ml, final total volume of 200 μl / well, and the cells were incubated for an additional 72 hours at 37° C., 5% CO2. All cultures were performed in triplicate.

[0110] At the end of this incubation, cell proliferation was determined as des...

example 3

[0117] Whole blood was drawn from GR191, a normal human volunteer, and processed as described in Example 1 to give heat-inactivated serum and PBL. The compound of formula II and methylphenidate in culture medium (made using heat-inactivated GR191 serum) were added to wells of a 96-well plate to give final concentrations of 5 μg / ml, 15 μg / ml, 25 μg / ml and 50 μg / ml of the compound of formula II and 50 μg / ml methylphendiate. Water, mouse nerve growth factor (Upstate Biotechnology, Inc) (NGF) (final concentration of 250 ng / ml) and dexamethasone (final concentration of 10 μM) were used as controls. Then, GR191's PBL in culture medium were added to the wells to give a final concentration of 150,000 cells per well, and the plates were incubated at 37° C., 5% CO2 for 24 hours. After this incubation, PHA was added to give final concentrations of 2 μg / ml and 5 μg / ml, final total volume of 200 μl / well, and the cells were incubated for an additional 72 hours at 37° C., 5% CO2. All cultures were...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Login to view more

Abstract

The present invention provides methods of using compounds of formula I:
and salts and prodrugs thereof, wherein n, R1 and R2 are defined herein. The invention also provides certain novel compounds of formula I and pharmaceutical compositions comprising them.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims benefit of provisional applications Nos. 60 / 645,778, filed Jan. 20, 2005, and 60 / 663,006, filed Mar. 18, 2005, the complete disclosures of which are incorporated herein by reference.FIELD OF THE INVENTION [0002] The invention relates to uses of methylphenidate derivatives. The uses include inhibiting angiogenesis and treating angiogenic diseases and conditions. BACKGROUND [0003] Methylphenidate is the treatment of choice for children and adults diagnosed with attention deficit / hyperactivity disorder (ADHD), including its inattentive subtype (formerly known as attention deficit disorder or ADD). Certain derivatives of methylphenidate have also been proposed for the treatment of ADD (see U.S. Pat. No. 6,025,502) and for the treatment of other neurological disorders and conditions (see U.S. Pat. Nos. 5,859,249, 6,025,502 and 6,486,177 and PCT application WO 99 / 36403). [0004] Methylphenidate is a mild central nervous...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/445
CPCA61K31/445A61P3/04A61P3/10A61P7/00A61P9/00A61P9/10A61P15/00A61P17/00A61P17/06A61P19/02A61P25/22A61P27/02A61P27/06A61P35/00A61P35/02A61P35/04A61P37/06C07D295/145
Inventor BAR-OR, DAVIDRAO, NAGARAJA R.K.
Owner AMPIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap